GlaxoSmithKline plc (GSK.L,GSK) announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare for mepolizumab as an add-on maintenance treatment for for adults and adolescents aged 12 years or older with severe eosinophilic asthma who experience exacerbations on standard treatment.
Mepolizumab is not currently approved for use anywhere in the world. The company said regulatory filings in a number of other countries, including the US and EU, are underway.
For comments and feedback contact: editorial@rttnews.com
Business News